{
    "eid": "2-s2.0-85143168869",
    "title": "Cost-Utility Analysis of Biologic Disease-Modifying Antirheumatic Drugs for Patients With Psoriatic Arthritis in Thailand",
    "cover-date": "2023-03-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Economics, Econometrics and Finance (miscellaneous)",
            "@code": "2001",
            "@abbrev": "ECON"
        },
        {
            "@_fa": "true",
            "$": "Pharmacology, Toxicology and Pharmaceutics (miscellaneous)",
            "@code": "3001",
            "@abbrev": "PHAR"
        },
        {
            "@_fa": "true",
            "$": "Health Policy",
            "@code": "2719",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "biologic disease-modifying antirheumatic drugs",
        "cost-effectiveness analysis",
        "cost-utility analysis",
        "economic evaluation",
        "psoriatic arthritis"
    ],
    "authors": [
        "Piyameth Dilokthornsakul",
        "Ratree Sawangjit",
        "Manathip Osiri",
        "Praveena Chiowchanwisawakit",
        "Worawit Louthrenoo",
        "Unchalee Permsuwan"
    ],
    "citedby-count": 1,
    "ref-count": 26,
    "ref-list": [
        "Prevalence and incidence of psoriatic arthritis: a systematic review and meta-analysis",
        "Psoriatic arthritis: epidemiology, clinical features, course, and outcome",
        "Treatment guidelines in psoriatic arthritis",
        "Understanding the relationship between the EQ-5D, SF-6D, HAQ and disease activity in inflammatory arthritis",
        "Evaluation of the economic burden of psoriatic arthritis and the relationship between functional status and healthcare costs",
        "The CEDAR study: a longitudinal study of the clinical effects of conventional DMARDs and biologic DMARDs in Australian rheumatology practice",
        "European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update",
        "Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis",
        "Guideline for management of psoriatic arthritis. Thai Rheumatism Association",
        "Cost-effectiveness analysis of secukinumab versus other biologics and apremilast in the treatment of active psoriatic arthritis: a Finnish perspective",
        "Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective",
        "Health technology assessment in Thailand: institutionalization and contribution to healthcare decision making: review of literature",
        "Health technology assessment process guidelines. Health Intervention and Technology Assessment Program",
        "Guidelines for Health Technology Assessment in Thailand",
        "Guidelines for Health Technology Assessment in Thailand",
        "Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation",
        "Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics/apremilast: a network meta-analysis",
        "Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death",
        "Standard cost lists for health technology assessment (in Thai language). Health Intervention and Technology Assessment Program",
        "Consumer price Index, Bureau of Trade and Economic Indices.",
        "Thai Baht to US Dollar Spot Exchange Rates for 2019. Exchange Rates UK",
        "The EQ-5D-5L valuation study in Thailand",
        "Comprehensibility, reliability, validity, and responsiveness of the Thai version of the Health Assessment Questionnaire in Thai patients with rheumatoid arthritis",
        "Psoriasis assessment tools in clinical trials",
        "Estimating the willingness to pay for a quality-adjusted life year in Thailand: does the context of health gain matter?",
        "Cost and cost effectiveness of treatments for psoriatic arthritis: a systematic literature review"
    ],
    "affiliation": [
        {
            "affiliation-city": "Chaing Mai",
            "@id": "60000881",
            "affilname": "Chiang Mai University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60000881",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60199575",
            "affilname": "Siriraj Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60199575",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Chaing Mai",
            "@id": "60032250",
            "affilname": "Faculty of Medicine, Chiang Mai University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60032250",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Pitsanulok",
            "@id": "60022498",
            "affilname": "Naresuan University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022498",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Maha Sarakham",
            "@id": "60002875",
            "affilname": "Mahasarakham University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002875",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "Thai Food and Drug Administration",
        "Ministry of Public Health, Thailand"
    ]
}